• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Corvus Pharmaceuticals Inc.

    5/7/24 5:19:03 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVS alert in real time by email
    S-8 1 tmb-20240507xs8.htm S-8

    As filed with the Securities and Exchange Commission on May 7, 2024

    Registration No. 333-

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933


    Corvus Pharmaceuticals, Inc.

    (Exact name of Registrant as specified in its charter)

    ​

     

    Delaware
    (State or other jurisdiction of
    incorporation or organization)

    ​

    46-4670809
    (I.R.S. Employer
    Identification Number)

    ​

    863 Mitten Road, Suite 102

    Burlingame, CA 94010

    (650) 900-4520

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)


    2016 Equity Incentive Award Plan

    (Full Title of the Plan)


    Richard A. Miller, M.D.

    President and Chief Executive Officer

    Corvus Pharmaceuticals, Inc.

    863 Mitten Road, Suite 102

    Burlingame, CA 94010

    (650) 900-4520

    (Name, address, including zip code, and telephone number, including area code, of agent for service)


    Copies to:

    Phillip S. Stoup, Esq.
    Latham & Watkins LLP
    140 Scott Drive
    Menlo Park, CA 94025

    Telephone: (650) 328-4600

    Facsimile: (650) 463-2600


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

     

    ☐

      

    Accelerated filer

     

    ☐

    Non-accelerated filer

     

    ☒  

      

    Smaller reporting company

    ☒

    ​

    ​

    ​

    ​

    Emerging growth company

    ​

    ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

    ​

    Proposed sale to take place as soon after the effective date of the

    registration statement as awards under the plans are exercised and/or vest.

    ​

    ​


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,961,000 shares of the Registrant’s common stock issuable under the 2016 Equity Incentive Plan, for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-210456, 333-216590, 333-223622, 333-231331, 333-237933, 333-255614, 333-264718, and 333-270910) are effective, as a result of the operation of an automatic annual increase provision therein.

    ​


    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8

    ​

    Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on March 29, 2016, March 10, 2017, March 13, 2018, May 9, 2019, April 30, 2020, April 29, 2021, May 5, 2022 and March 28, 2023 (File Nos. 333-210456, 333-216590, 333-223622, 333-231331, 333-237933, 333-255614, 333-264718, and 333-270910) are incorporated by reference herein.

    ​

    ​


    Exhibit Index

     

    ​

     

        

    Incorporated by Reference

    ​

    Filed
    Herewith

    Exhibit
    Number

        

    Exhibit Description

        

    Form

        

    Date

        

    Number

        

    ​

    4.1

    ​

    Amended and Restated Certificate of Incorporation.

    ​

    8-K

    ​

    3/29/2016

    ​

    3.1

    ​

    ​

    4.2

    ​

    Amended and Restated Bylaws.

    ​

    8-K

    ​

    3/29/2016

    ​

    3.2

    ​

    ​

    4.3

    ​

    Form of Common Stock Certificate.

    ​

    S-1

    ​

    1/4/2016

    ​

    4.2

    ​

    ​

    5.1

    ​

    Opinion of Latham & Watkins LLP.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    X

    23.1

    ​

    Consent of independent registered public accounting firm.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    X

    23.2

    ​

    Consent of Latham & Watkins LLP (included in Exhibit 5.1).

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    X

    24.1

    ​

    Power of Attorney. Reference is made to the signature page to the Registration Statement.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    X

    99.2(a)#

    ​

    2016 Equity Incentive Award Plan.

    ​

    S-8

    ​

    3/29/2016

    ​

    99.2(a)

    ​

    ​

    99.2(b)#

    ​

    Form of Stock Option Grant Notice and Stock Option Agreement under the 2016 Equity Incentive Award Plan.

    ​

    S-1

    ​

    1/4/2016

    ​

    10.5(b)

    ​

    ​

    99.2(c)#

    ​

    Form of Restricted Stock Award Agreement and Restricted Stock Unit Award Agreement under the 2016 Equity Incentive Award Plan.

    ​

    S-1

    ​

    1/4/2016

    ​

    10.5(c)

    ​

    ​

    99.2(d)#

    ​

    Form of Restricted Stock Unit Award Agreement and Restricted Stock Unit Award Grant Notice under the 2016 Equity Incentive Award Plan.

    ​

    S-1

    ​

    1/4/2016

    ​

    10.5(d)

    ​

    ​

    107.1

    ​

    Calculation of Filing Fee Table

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    X

    ​

    #Indicates management contract or compensatory plan.

    ​

    ​


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Burlingame, California, on this 7th day of May, 2024.

    ​

    ​

    Corvus Pharmaceuticals, Inc.

     By:

    /s/ Richard A. Miller

    ​

    ​

    ​

     

    Richard A. Miller, M.D.

    ​

    ​

    ​

     

    President and Chief Executive Officer

    ​

    ​

    ​


    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Richard A. Miller, M.D. and Leiv Lea, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

    ​

    ​

    ​

    Signature 

        

    Title 

        

    Date 

    ​

    ​

    /s/ Richard A. Miller

    ​

    President, Chief Executive Officer and Director

    ​

    May 7, 2024

    Richard A. Miller M.D.

    ​

    (Principal Executive Officer)

    ​

    ​

    ​

    ​

    /s/ Leiv Lea

    ​

    Chief Financial Officer

    ​

    May 7, 2024

    Leiv Lea

    ​

    (Principal Financial and Accounting Officer)

    ​

    ​

    ​

    ​

    /s/ Ian T. Clark

    ​

    Director

    ​

    May 7, 2024

    Ian T. Clark

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Elisha P. (Terry) Gould

    ​

    Director

    ​

    May 7, 2024

    Elisha P. (Terry) Gould

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Linda S. Grais, M.D., J.D.

    ​

    Director

    ​

    May 7, 2024

    Linda S. Grais, M.D., J.D.

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Scott W. Morrison

    ​

    Director

    ​

    May 7, 2024

    Scott W. Morrison

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Peter Thompson, M.D.

    ​

    Director

    ​

    May 7, 2024

    Peter Thompson, M.D.

    ​

    ​

    ​

    ​

    ​


    Get the next $CRVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRVS

    DatePrice TargetRatingAnalyst
    10/13/2025$16.00Overweight
    Barclays
    1/2/2025$11.00Buy
    H.C. Wainwright
    8/18/2023$7.00Outperform
    Oppenheimer
    12/3/2021$5.00 → $8.00Overweight
    Cantor Fitzgerald
    12/1/2021$8.00Buy
    Jefferies
    8/3/2021$4.00 → $3.50Neutral
    Mizuho
    7/16/2021$9.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CRVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thompson Peter A. exercised 210,000 shares at a strike of $5.33 (SEC Form 4)

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    1/30/26 6:39:04 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Jones William Benton

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    12/8/25 4:23:09 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Miller Richard A Md

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    12/8/25 4:22:35 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

    SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,185,101 additional shares, at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $201.2 million, including proceeds from the full exercise of the underwriters' option to purchase additional shar

    1/23/26 5:00:15 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $175.0 million. All of the shares of common stock are being offered by Corvus. In addition, Corvus has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,185,101 shares of comm

    1/21/26 10:53:56 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

    SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the offering will be offered by Corvus. In addition, Corvus expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $22,500,000 of shares of common stock at the public offering price less underwriting disco

    1/20/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Corvus Pharmaceuticals Inc.

    SCHEDULE 13D/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

    2/5/26 10:29:55 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Corvus Pharmaceuticals Inc.

    SCHEDULE 13G - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

    1/30/26 1:26:05 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Corvus Pharmaceuticals Inc.

    SCHEDULE 13D/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

    1/27/26 8:38:38 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Corvus Pharmaceuticals with a new price target

    Barclays initiated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $16.00

    10/13/25 8:52:40 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Corvus Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $11.00

    1/2/25 7:32:41 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Corvus Pharmaceuticals with a new price target

    Oppenheimer initiated coverage of Corvus Pharmaceuticals with a rating of Outperform and set a new price target of $7.00

    8/18/23 8:04:45 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jones William Benton bought $34,624 worth of shares (20,000 units at $1.73), increasing direct ownership by 15% to 153,773 units (SEC Form 4)

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    5/7/24 5:06:34 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Miller Richard A Md bought $1,000,000 worth of shares (577,634 units at $1.73) (SEC Form 4)

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    5/7/24 5:05:52 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Leadership Updates

    Live Leadership Updates

    View All

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Corvus Pharmaceuticals Appoints David Moore to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., has been appointed to the company's Board of Directors. Mr. Moore brings a wealth of experience from his 27-year career in the industry, including broad expertise across strategy, commercial, market access, business development and investing from working in both large cap pharmaceutical and biotech companies and within private equity. "We are excited to welcome David to the Board," said Richard A. Miller, M.D., c

    10/2/25 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

    SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company's board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board member. "We're thrilled to welcome Richard to our board," said Richard A. Miller, M.D., chairman, president and chief executive officer of Corvus. "Richard has a proven track record in the biotechnology sector and a deep understanding of the global pharmaceutic

    4/9/25 4:01:54 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Financials

    Live finance-specific insights

    View All

    Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

    Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment  75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and 33% achieved IGA 0/1 Cohort 1-4 have demonstrated positive safety and efficacy results in patients who have received prior systemic therapy including patients who are treatment resistant Company to host conference call and webcast today at 8:00 am ET / 5:00 am PT SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced positive results from cohort 4 of the randomized,

    1/20/26 7:00:00 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

    SOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT) to report the results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. Conference Call, Webcast and Presentation SlidesThe conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live we

    1/16/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

    Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic dermatitis phase 2 trial on track to initiate in early Q1 2026 Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open; final Phase 1/1b results accepted for oral presentation at the American Society of Hematology Annual Meeting Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:

    11/4/25 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc.

    SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

    8/1/24 9:18:47 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

    5/13/24 4:52:14 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Corvus Pharmaceuticals Inc.

    SC 13G - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

    5/9/24 5:29:29 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care